EMA says Bayer’s Diane-35 has more benefit than risk
France drug regulator in January yanked...
Read more
Read more
Archive for the 'drug' tag
EMA says Bayer’s Diane-35 has more benefit than risk
France drug regulator in January yanked...
Read more
Read more
Docs call drugmakers ‘profiteers’ for costs of cancer meds
Sanofi ( $SNY ) is not very popular among its...
Read more
Read more
Pfizer appealing CHMP ruling on RA treatment Xeljanz
Pfizer has big expectations for its oral...
Read more
Read more
Biogen MS pill soars onstage with impressive first-week script numbers
Biogen Idec's ( $BIIB ) new? multiple...
Read more
Read more
Treatment for novel coronavirus shows promise in early lab tests
National Institutes of Health (NIH) scientists...
Read more
Read more
Arrhythmia drug may increase cancer risk
One of the most widely used medications to treat...
Read more
Read more
GlaxoSmithKline aims to pump up Benlysta with new vasculitis use
How can GlaxoSmithKline ( $GSK ) jump-start...
Read more
Read more
J&J faces big spending, big rivals for new diabetes drug Invokana
Johnson & Johnson's new diabetes drug...
Read more
Read more
FDA saw early reports of severe Omontys reactions: WSJ
The anemia drug Omontys triggered serious...
Read more
Read more
Pfizer TB drug joins shortage parade after potency warning
Yet another tuberculosis drug has joined the...
Read more
Read more
J&J fights $327M Risperdal verdict, saying no one was harmed
South Carolina Circuit Judge Roger Couch took a...
Read more
Read more
Drug Does Not Significantly Reduce Risk of Death Among Patients With Severe Sepsis
CHICAGO – Administration of the drug...
Read more
Read more
Vivus investor plots board takeover to rally Qsymia sales
Vivus may rue the day that it decided to go solo...
Read more
Read more
Bayer wins new use for fast-moving cancer drug Stivarga
Bayer's new cancer drug Stivarga has already...
Read more
Read more
With nod, Roche’s Kadcyla should quickly become blockbuster
At an earnings call last month, Roche ( $RHHBY )...
Read more
Read more
EMA again pounds Vivus over Qsiva
Vivus' ( $VVUS ) weight-loss drug Qsymia was...
Read more
Read more
German cost agency spurns Xalkori, Komboglyze
The well-armed German pricing gatekeepers have...
Read more
Read more
Marijuana Drug Abuse in The usa
Marijuana is one of the earliest unlawful drugs...
Read more
Read more
Novartis nabs another FDA-approved indication for everolimus
Zortress nabbed another approval.–Courtesy...
Read more
Read more
Sanofi plots Irish plant investment to boost Lantus supply
Sanofi ( $SNY ) is plowing new money into Genzyme...
Read more
Read more
Turns out, Vivus’ slow launch of Qsymia may be best plan
Crash diets can be all the rage but quickly fade...
Read more
Read more
Bevacizumab Significantly Improves Survival for Patients With Recurrent and Metastatic Cervical Cancer
Patients with advanced, recurrent, or persistent...
Read more
Read more
Swamped with generics, Sanofi rides Lantus to dry land
Where would Sanofi be without Lantus ? The...
Read more
Read more
Merck loses ‘bellwether’ Fosamax case
A judge says Merck wasn't up front about the...
Read more
Read more